GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as…
GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, announced it has closed on a Series A financing generating…
Read More...
Read More...
